Cover Story
Free
As administrations change, cancer research stands in an unusually strong position, NCI Acting Director Douglas Lowy said in an interview with The Cancer Letter.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Menin inhibitors emerge as new treatment for advanced AML
- Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes